Oral administration is the most common delivery method for medicines. This webinar focuses on the design of dissolution media to support biopredictive dissolution testing. It highlights a method for selecting practical, physiologically relevant media based upon the drug formulation, and GI fluid properties. Learn how the interplay between drug, formulation, and gastrointestinal (GI) fluid properties impacts drug solubility and dissolution. Click here to learn more.
William B. Jones, senior vice president of pharmaceutical development at Corvus Pharmaceuticals, discusses his company’s selection of CDMO for its CPI-006 antibody program, which is currently under development as an oncology drug and investigation as a therapeutic for immune disorders and infectious diseases.
By Laura McAleer and Catriona Thomson,Sartorius
Many new therapies are targeting the PD-1 pathway to boost the immune response to cancer cells. Current assays used to measure the activity of anti-PD-1 or anti-PD-L1 antibodies can be highly variable due to their reliance on primary cells and complex assay protocols. One method to demonstrate the activity of anti PD-1 molecules using a functionally relevant but less variable method is using a potency ELISA.
By implementing a digital lab solution, you can bridge the innovation and productivity gaps in research, development, manufacturing and quality, and enable successful technology transfer across new product development and production operations.
On this week's Business of Biotech, Dr. Judy Chou, president and CEO at AltruBio, shares personal and professional insight into how she's applied what she's learned in Big Bio to transform a clinical-stage developer of monoclonal antibodies (mAbs) designed to treat a broad range of immunological diseases. Listen now and subscribe so you never miss an episode.